Get Naltrexone
Treatment & Safety

Naltrexone Contraindications: Opioids, Withdrawal, and Label Checks

Current opioid use, opioid dependence, acute withdrawal, specified test results, and prior hypersensitivity can make naltrexone unsafe to start.

4 minute read
Patient and clinician review a safety gateway between an opioid symbol and a clinical check mark

A contraindication is not the same as a precaution

A contraindication is a labelled reason not to use a product. A warning, precaution, or clinical consideration is different: it signals that a clinician needs to weigh the risk, examine the current label, or monitor more closely. This distinction follows the current Vivitrol label and is why a general web list cannot decide whether an individual can start treatment.

That distinction matters for naltrexone. Recent opioid exposure can make initiation unsafe because naltrexone blocks opioid receptors and can trigger abrupt, severe withdrawal in a person who is physically dependent. Liver symptoms, mental-health symptoms, kidney function, pregnancy, and planned pain treatment also matter, but the exact status depends on the product label and the individual clinical situation.

Current US-label contraindications

The current Vivitrol label’s contraindications section lists:

  • receiving opioid analgesics;
  • current physiologic opioid dependence;
  • acute opioid withdrawal;
  • a failed naloxone challenge test or a positive urine screen for opioids; and
  • previous hypersensitivity to naltrexone, the Vivitrol microsphere polymer, the diluent ingredients, or another component of the product.

The oral naltrexone tablet label likewise centres on current opioids, opioid dependence or withdrawal, specified opioid-test results, and prior hypersensitivity. Do not assume that a brand, formulation, country, or combination product has identical wording. Read the current label for the exact product being considered.

Why a complete opioid history is essential

The opioid review needs to include more than heroin or prescription pain medicines. Tell the clinician about all recent use of:

  • opioid pain medicines, whether prescribed or not;
  • buprenorphine, buprenorphine/naloxone, or methadone;
  • tramadol;
  • opioid-containing cough, cold, or anti-diarrhoeal products; and
  • non-prescribed or unknown substances that could contain an opioid.

This is important even if naltrexone is being considered for alcohol use disorder rather than opioid use disorder. The oral tablet label describes cases of precipitated withdrawal in people treated for alcohol dependence when the prescriber was unaware of opioid use or dependence.

Does liver disease automatically rule out naltrexone?

Not from a generic online list. Liver disease is not named in the Vivitrol contraindications list quoted above, but both the Vivitrol and oral labels include liver-injury warnings and call for medical assessment of symptoms consistent with acute hepatitis. That means a clinician must assess the exact product, liver history, symptoms, tests where appropriate, and the risks of untreated alcohol or opioid use disorder. It is not a self-clearance to start or continue treatment.

Conditions that still need a clinician’s judgement

Do not turn a general online list into a personal eligibility decision. For example, product labels warn about liver injury and advise assessment of symptoms consistent with acute hepatitis; they also discuss depression or suicidality, overdose vulnerability, and—specific to Vivitrol—serious injection-site reactions. These are important safety issues, but they are not a substitute for reading the product’s contraindications section.

Similarly, Vivitrol and oral naltrexone are not interchangeable with Contrave, the naltrexone/bupropion combination product used for chronic weight management. They have different doses, indications, ingredients, and safety information.

Questions to take to the prescriber

  1. Which exact naltrexone product and indication are we considering?
  2. Could any medicine, treatment, or non-prescribed substance I used recently contain an opioid?
  3. Am I experiencing opioid withdrawal symptoms now?
  4. Is a urine screen or clinician-supervised naloxone challenge appropriate in this situation?
  5. Do liver symptoms, a past reaction, mental-health symptoms, or an upcoming need for opioid pain treatment change the plan?

For the opioid-free interval and the limits of testing, read Starting Naltrexone After Opioids.

Primary sources

  1. DailyMed: Vivitrol prescribing information

    US label, revised December 2025; contraindications and safety warnings.

  2. DailyMed: naltrexone hydrochloride tablet prescribing information

    US oral-tablet label; opioid-related contraindications and initiation warnings.

Share article